Cargando…

Pharmacological Modulation of Calcium Homeostasis in Familial Dilated Cardiomyopathy: An In Vitro Analysis From an RBM20 Patient‐Derived iPSC Model

For inherited cardiomyopathies, abnormal sensitivity to intracellular calcium (Ca(2+)), incurred from genetic mutations, initiates subsequent molecular events leading to pathological remodeling. Here, we characterized the effect of β‐adrenergic stress in familial dilated cardiomyopathy (DCM) using h...

Descripción completa

Detalles Bibliográficos
Autores principales: Wyles, SP, Hrstka, SC, Reyes, S, Terzic, A, Olson, TM, Nelson, TJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902766/
https://www.ncbi.nlm.nih.gov/pubmed/27105042
http://dx.doi.org/10.1111/cts.12393
_version_ 1782437025241104384
author Wyles, SP
Hrstka, SC
Reyes, S
Terzic, A
Olson, TM
Nelson, TJ
author_facet Wyles, SP
Hrstka, SC
Reyes, S
Terzic, A
Olson, TM
Nelson, TJ
author_sort Wyles, SP
collection PubMed
description For inherited cardiomyopathies, abnormal sensitivity to intracellular calcium (Ca(2+)), incurred from genetic mutations, initiates subsequent molecular events leading to pathological remodeling. Here, we characterized the effect of β‐adrenergic stress in familial dilated cardiomyopathy (DCM) using human‐induced pluripotent stem cell (hiPSC)‐derived cardiomyocytes (CMs) from a patient with RBM20 DCM. Our findings suggest that β‐adrenergic stimulation accelerated defective Ca(2+) homeostasis, apoptotic changes, and sarcomeric disarray in familial DCM hiPSC‐CMs. Furthermore, pharmacological modulation of abnormal Ca(2+) handling by pretreatment with β‐blocker, carvedilol, or Ca(2+)‐channel blocker, verapamil, significantly decreased the area under curve, reduced percentage of disorganized cells, and decreased terminal deoxynucleotidyl transferase‐mediated deoxyuridine triphosphate nick‐end labeling (TUNEL)‐positive apoptotic loci in familial DCM hiPSC‐CMs after β‐adrenergic stimulation. These translational data provide patient‐based in vitro analysis of β‐adrenergic stress in RBM20‐deficient familial DCM hiPSC‐CMs and evaluation of therapeutic interventions to modify heart disease progression, which may be personalized, but more importantly generalized in the clinic.
format Online
Article
Text
id pubmed-4902766
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-49027662016-09-23 Pharmacological Modulation of Calcium Homeostasis in Familial Dilated Cardiomyopathy: An In Vitro Analysis From an RBM20 Patient‐Derived iPSC Model Wyles, SP Hrstka, SC Reyes, S Terzic, A Olson, TM Nelson, TJ Clin Transl Sci Research For inherited cardiomyopathies, abnormal sensitivity to intracellular calcium (Ca(2+)), incurred from genetic mutations, initiates subsequent molecular events leading to pathological remodeling. Here, we characterized the effect of β‐adrenergic stress in familial dilated cardiomyopathy (DCM) using human‐induced pluripotent stem cell (hiPSC)‐derived cardiomyocytes (CMs) from a patient with RBM20 DCM. Our findings suggest that β‐adrenergic stimulation accelerated defective Ca(2+) homeostasis, apoptotic changes, and sarcomeric disarray in familial DCM hiPSC‐CMs. Furthermore, pharmacological modulation of abnormal Ca(2+) handling by pretreatment with β‐blocker, carvedilol, or Ca(2+)‐channel blocker, verapamil, significantly decreased the area under curve, reduced percentage of disorganized cells, and decreased terminal deoxynucleotidyl transferase‐mediated deoxyuridine triphosphate nick‐end labeling (TUNEL)‐positive apoptotic loci in familial DCM hiPSC‐CMs after β‐adrenergic stimulation. These translational data provide patient‐based in vitro analysis of β‐adrenergic stress in RBM20‐deficient familial DCM hiPSC‐CMs and evaluation of therapeutic interventions to modify heart disease progression, which may be personalized, but more importantly generalized in the clinic. John Wiley and Sons Inc. 2016-04-22 2016-06 /pmc/articles/PMC4902766/ /pubmed/27105042 http://dx.doi.org/10.1111/cts.12393 Text en © 2016 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research
Wyles, SP
Hrstka, SC
Reyes, S
Terzic, A
Olson, TM
Nelson, TJ
Pharmacological Modulation of Calcium Homeostasis in Familial Dilated Cardiomyopathy: An In Vitro Analysis From an RBM20 Patient‐Derived iPSC Model
title Pharmacological Modulation of Calcium Homeostasis in Familial Dilated Cardiomyopathy: An In Vitro Analysis From an RBM20 Patient‐Derived iPSC Model
title_full Pharmacological Modulation of Calcium Homeostasis in Familial Dilated Cardiomyopathy: An In Vitro Analysis From an RBM20 Patient‐Derived iPSC Model
title_fullStr Pharmacological Modulation of Calcium Homeostasis in Familial Dilated Cardiomyopathy: An In Vitro Analysis From an RBM20 Patient‐Derived iPSC Model
title_full_unstemmed Pharmacological Modulation of Calcium Homeostasis in Familial Dilated Cardiomyopathy: An In Vitro Analysis From an RBM20 Patient‐Derived iPSC Model
title_short Pharmacological Modulation of Calcium Homeostasis in Familial Dilated Cardiomyopathy: An In Vitro Analysis From an RBM20 Patient‐Derived iPSC Model
title_sort pharmacological modulation of calcium homeostasis in familial dilated cardiomyopathy: an in vitro analysis from an rbm20 patient‐derived ipsc model
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902766/
https://www.ncbi.nlm.nih.gov/pubmed/27105042
http://dx.doi.org/10.1111/cts.12393
work_keys_str_mv AT wylessp pharmacologicalmodulationofcalciumhomeostasisinfamilialdilatedcardiomyopathyaninvitroanalysisfromanrbm20patientderivedipscmodel
AT hrstkasc pharmacologicalmodulationofcalciumhomeostasisinfamilialdilatedcardiomyopathyaninvitroanalysisfromanrbm20patientderivedipscmodel
AT reyess pharmacologicalmodulationofcalciumhomeostasisinfamilialdilatedcardiomyopathyaninvitroanalysisfromanrbm20patientderivedipscmodel
AT terzica pharmacologicalmodulationofcalciumhomeostasisinfamilialdilatedcardiomyopathyaninvitroanalysisfromanrbm20patientderivedipscmodel
AT olsontm pharmacologicalmodulationofcalciumhomeostasisinfamilialdilatedcardiomyopathyaninvitroanalysisfromanrbm20patientderivedipscmodel
AT nelsontj pharmacologicalmodulationofcalciumhomeostasisinfamilialdilatedcardiomyopathyaninvitroanalysisfromanrbm20patientderivedipscmodel